Objective:To investigate biomarkers for sarcopenia in chronic kidney disease(CKD).Methods:Data from CHARLS 2011 were used for a cross-sectional study.CKD was diagnosed based on self-reported kidney disease history and/or eGFR<60 ml/min·1.73 m2.Sarcopenia and possible sarcopenia were diagnosed according to the 2019 expert consensus of the Asian Working Group for Sarcopenia(AWGS).The Creatinine Muscle Index(CMI)is the product of blood creatinine and the estimated glomerular filtration rate by cystatin C.Logistic regression analysis was used to investigate the association between CMI and sarcopenia in CKD.Results:A total of 1008 CKD patients were included,with 119 cases of sarcopenia,a prevalence of 11.8%,and 344 cases of possible sarcopenia,a prevalence of 34.1%.CMI showed an L-shaped relationship with the occurrence of sarcopenia,with low risk of sarcopenia when CMI was between 50-60.The risk of sarcopenia is lowered by 2.7%for every one-unit increase in CMI.The optimal cutoff value of CMI for diagnosing sarcopenia in CKD was 50.92,with an area under the curve(AUC)of 0.715.Conclusion:The prevalence of sarcopenia in the community CKD population is high,and CMI can serve as a biological diagnostic indicator for sarcopenia in CKD.
维普
万方数据